Synthetic Medicines and Phytopharmaceuticals: their Potential Equivalence
The present study suggests that, with adequate R&D investment, native plant species may provide an alternative to replace synthetic drugs. 21 synthetic drugs, from 14 pharmacologically different classes, were evaluated. The conclusion was that native species did, in fact, have a good potenti...
| Autores: | , |
|---|---|
| Tipo de documento: | artigo |
| Estado: | Versão publicada |
| Data de publicação: | 2005 |
| País: | Brasil |
| Recursos: | Fundação Oswaldo Cruz (FIOCRUZ) |
| Repositório: | Revista Fitos |
| Idioma: | português |
| OAI Identifier: | oai:ojs.revistafitos.far.fiocruz.br:article/5 |
| Acesso em linha: | https://revistafitos.far.fiocruz.br/index.php/revista-fitos/article/view/5 |
| Access Level: | Acceso aberto |
| Palavra-chave: | plantas medicinais medicamento fitoterápico política de saúde medicinal plants phytomedicine public health |
| Resumo: | The present study suggests that, with adequate R&D investment, native plant species may provide an alternative to replace synthetic drugs. 21 synthetic drugs, from 14 pharmacologically different classes, were evaluated. The conclusion was that native species did, in fact, have a good potential to replace, at least a part of their synthetic analogues at lower cost and using national technology. This potentiality can become a reality through public-private partnerships, given financial subsidies and the inclusion of phytomedicine in the National Medicine List - RENAME. This strategy may contribute, with the expansion of the phytopharmaceutical industry, by promoting the use of medicinal plants as a class of safe and efficient drugs, to better accessibility to all Brazilians citizens as well as by replacing the present importation of synthetic drugs by insertion of the phytomedicinal products into the international market. |
|---|